Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma Jan 4 Written by Mukul Verma Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center ISACFF Mukul Verma Previous Previous Ovarian cancer survivor: Immunotherapy clinical trial saved my life Next Next Israeli biotech company begins trial for cancer immuno-oncology solution
Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma Jan 4 Written by Mukul Verma Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center ISACFF Mukul Verma
